ibudilast

Categories
  1. MN-166 (ibudilast) to enter phase III clinical trials for progressive MS

    MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

    pipette samples

    Read more »
  2. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Read more »
  3. FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials

    Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

    FDA Ibudilast molecule and pills

    Read more »
US 0